HealthLinx Inks Deals for Prostate Cancer Biomarkers, Ovarian Cancer Dx

Garvan Institute will evaluate HealthLinx's prostate cancer biomarkers under one deal, while CPC Clinical Research will liaise with the FDA for HealthLinx's OvPlex test under a separate agreement.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.